WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

International Federation of Clinical Chemistry and Laboratory Medicine

Acronym (if applicable)

IFCC

Short self description

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is a global professional association that promotes the fields of clinical chemistry and laboratory medicine. It was established in 1952 as the International Association of Clinical Biochemists to organize the various national societies of these fields. The IFCC's aims are to set global standards, support and educate its members, and provide conferences and other gatherings for sharing knowledge among the global laboratory medicine community. IFCC members fall into three groups: national societies of clinical chemistry and laboratory medicine, corporations, and affiliate international or national societies involved in laboratory medicine.

Website

http://www.ifcc.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

29 Aug 2024 04:35:35 PM

General information

Name

Official name

International Federation of Clinical Chemistry and Laboratory Medicine

Acronym (if applicable)

IFCC

Commonly used name (if applicable)

Names in other official languages (if applicable) Name Abbreviation

International Federation of Clinical Chemistry and Laboratory Medicine

IFCC

Former name

Short self description

Address Contact

Address 1

c/o Seedamm Business Center, Churerstrasse, 135

Address 2

Address 3

Town/City

Pfaeffikon

State/Region

Postal code

8808

Country

Switzerland

Email (generic)

ifcc@ifcc.org

Related links

Website

http://www.ifcc.org

Governance

Legal status

Non Profit Organization

Year established

1952

Governance structure

Description of main decision making bodies (e.g. board, board of directors, executive board, executive committee, etc).

Name of body

Executive Board

Composition and current list of members Name Function Affiliation

Prof. Tomris Ozben

President

Professor Medical Biochemistry, Akdeniz University-Medical Faculty, Antalya-Türkiye

Prof. Khosrow Adeli

Past-President

Head Clinical Biochemistry Paediatric Laboratory Medicin Department, The Hospital for Sick Children-Toronto, ON-Canada

Prof. Sergio Bernardini

Secretary

Professor Clinical Biochemistry Molecular Biology, University Tor Vergata, Rome-Italy

Dr. Alexander Haliassos

Treasurer

Director, Greek Proficiency Testing Scheme for Clinical Labs-Athens-Greece

Ms. Tricia Ravalico

Corporate Representative

Director, Global Scientific Leadership and Education, Abbott IL-USA

Prof. Rajiv Erasmus

EB Reg Fed Rep - African Fed Clinical Chemistry-AFCC

Professor Chemical Pathology, Tygerberg University, South Africa

Prof. Osama Najjar

EB Reg Fed Rep - Arab Fed Clinical Biology-AFCB

Deputy Assistant Allied Health Professions and Blood Banks, Ministry of Health (MOH) - Occupied Palestinian Territory

Dr. Tony Badrick

EB Reg Fed Rep - Asia-Pacific Fed Clinical Biochemistry Lab Med-APFCB

Chief Executive, The Royal College of Pathologists of Australia, St Leonards NSW - Australia

Dr. Eduardo Freggiaro

EB Reg Fed Rep - Latin-American Confed Clinical Biochemistry -COLABIOCLI

President, Fundación Bioquímica Argentina, Buenos Aires - Argentina

Dr. David Grenache

EB Reg Fed Rep - North American Fed Clinical Chemistry Lab Med-NAFCC

Professor of Pathology, University of New Mexico, Albuquerque, NM USA

Prof. Mario Plebani

EB Reg Fed Rep - European Fed Clinical Chemistry and Lab Med

Professor, Dept of Laboratory Medicine, University Hospital Padova- Italy

Functions

The Executive Board is charged with the day-to-day management of the Federation. The Executive Board shall ensure the orderly discharge of the functions of the Federation and, in particular, carry out the administrative duties between meetings of Council.

Name of body

Composition and current list of members Name Function Affiliation

Functions

General Assembly

Does the entity have a General Assembly of members or a similar body?

Yes

Name

IFCC Council

Composition

IFCC Full Members Societies' Representatives (actually 96)

Functions

The supreme body of the Federation shall be a Council which is responsible for the establishment of policy and the overall direction of the Federation. Council may exercise its authority at a meeting or when written submissions are presented to it according to the protocol. Full Members constitute the voting members of Council and vote the Executive Board Members.

Financial information

Latest available annual income (month/year)

From

January

2022

December

2022

Annual income (USD)

2,600,000

Latest available assets (month/year)

As of

December

2022

Total assets (USD)

Income sources (in USD)

Income source Income type

Private sector entities (including business associations)

Philanthropic foundations

NGOs, academic institutions

Government entities, intergovernmental organizations, including UN

General public, individuals

Total

Sales of goods and services *

1,700,000

Grants / Donations

94,000

In-kind donations

Membership fees

425,000

217,000

642,000

Investment income

63,000

Others

101,000

Total

2,383,000

217,000

2,600,000

* income from congresses / conferences should be listed under Sales of goods and services

Additional information

Membership

Entity's members

Is the entity you represent membership based?

Yes

Overview of categories and their voting rights in the main governing body:

Total number Voting

Individuals

NGOs

119

Private sector entities

Philanthropic foundations

Academic institutions

Government entities

Intergovernmental organizations

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Members of the entity

In the register Registered Entity Member Name

No data available

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

To:
- Advance the theory and practice of clinical laboratory science and to further its application in the provision of health services and the practice of medicine;
- Establish, inter alia, encourage and foster high professional standards of clinical laboratory science;
- Promote international cooperation and coordination in the development of clinical laboratory science in matters of research, procedures, materials, regulations and practices, education and training, codes of ethics and related subjects;
- Provide a basis for closer liaison and the free exchange of professional information among clinical laboratory scientists worldwide;
- Sponsor and support International Congresses, etc...
- Encourage, sponsor and/or conduct studies, prepare recommendations, reference measurement procedures and reference materials, reviews and reports on facets of clinical laboratory science of international interest and concern
- Assist in the organisation and establishment of new societies.

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic objective 1: Respond to climate change, an escalating health threat in the 21st century

Joint outcome 1.1. More climate-resilient health systems are addressing health risks and impacts

Joint outcome 1.2. Lower-carbon health systems and societies are contributing to health and well-being

Strategic objective 2: Address health determinants and the root causes of ill health in key policies across sectors

Joint outcome 2.1. Health inequities reduced by acting on social, economic, environmental and other determinants of health

Joint outcome 2.2. Priority risk factors for noncommunicable and communicable diseases, violence and injury, and poor nutrition, reduced through multisectoral approaches

Joint outcome 2.3. Populations empowered to control their health through health promotion programmes and community involvement in decision-making

Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage

Joint outcome 3.1. The primary health care approach renewed and strengthened to accelerate universal health coverage

Joint outcome 3.2. Health and care workforce, health financing and access to quality-assured health products substantially improved

Joint outcome 3.3. Health information systems strengthened and digital transformation implemented.

Strategic objective 4: Improve health service coverage and financial protection to address inequity and gender inequalities

Joint outcome 4.1. Equity in access to quality services improved for noncommunicable diseases, mental health conditions and communicable diseases, while addressing antimicrobial resistance

Joint outcome 4.2. Equity in access to sexual, reproductive, maternal, newborn, child, adolescent and older person health and nutrition services and immunization coverage improved

Joint outcome 4.3. Financial protection improved by reducing financial barriers and out-of-pocket health expenditures, especially for the most vulnerable

Strategic objective 5: Prevent, mitigate and prepare for risks to health from all hazards

Joint outcome 5.1. Risks of health emergencies from all hazards reduced and impact mitigated

Joint outcome 5.2. Preparedness, readiness and resilience for health emergencies enhanced

Strategic objective 6: Rapidly detect and sustain an effective response to all health emergencies

Joint outcome 6.1. Detection of and response to acute public health threats is rapid and effective

Joint outcome 6.2. Access to essential health services during emergencies is sustained and equitable

Additional information on the entity's activities

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

As indicated in IFCC Statutes' preamble:
Clinical Chemistry and Laboratory Medicine involves the study and application of chemistry, biochemistry, and molecular biology to the practice of diagnosis in Medicine. The scope of the subject matter of this discipline is recognised by several names in various parts of the world (e.g. clinical biochemistry, physiological chemistry,
chemical pathology). Included in its scope are the chemical facets of all areas of laboratory medicine. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) was formed to advance the science and practice of laboratory medicine throughout the world in the interest of the peoples of the world.

Pharmaceutical

Corporate Members cooperates with IFCC offering services for the field of clinical laboratory science.

Others

Please specify industry

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted